Dinesh V. Patel, Ph.D., President and CEO of Protagonist Therapeutics (PTGX), has demonstrated a consistent pattern of selling activity in the company’s stock over the past year, with no recent purchases recorded in SEC filings. Since July 2025, Patel has executed multiple sales totaling approximately $15.9 million, with the most significant transactions occurring in early 2026. Notably, on January 20, 2026, he sold shares worth $2.84 million, followed by additional sales totaling $1.63 million on January 23 and $2.09 million across January 26-27. The selling trend continued in March 2026, with a $5.52 million transaction on March 25. These sales were often accompanied by smaller transactions marked as "M" (likely market sales or option exercises), such as $306,543 on January 26 and $468,819 on March 25.
Patel’s trading history reveals a clear divestment strategy, with all 25 recorded transactions since mid-2025 involving sales or dispositions. The absence of any recent buys—coupled with the scale of disposals—suggests a deliberate reduction in his PTGX holdings. While some transactions, such as those labeled "G" or "A," appear to involve grants or awards with no reported value, the overwhelming majority reflect outright sales. The concentrated activity in PTGX, the only company associated with his filings, underscores a focused approach to liquidating his position in the biopharmaceutical firm. The timing and frequency of these sales, particularly the clustered disposals in early 2026, indicate a structured exit rather than sporadic adjustments.
AI-assisted summary